Tu1511 Pancreatitis Prior to Pancreatic Cancer: Clinical Features and Influence on Outcome

Dzeletovic, Ivana; Harrison, M. Edwyn; Decker, G. Anton; Pannala, Rahul; Nguyen, Cuong C.; Wu, Qing; Faigel, Douglas O.

doi:10.1016/s0016-5085(12)63304-6

Cited by 11 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Carlsen et al [27] used chronic pancreatitis patients as controls instead of normal healthy donors. It is uncertain why chronic pancreatitis patients were used as controls considering only a small population (8%) of pancreatic cancer patients have concomitant chronic pancreatitis [37] . There is a weak link between pancreatitis and pancreatic cancer [38] , and only 4% of patients within 20 years of chronic pancreatitis diagnosis have developed into pancreatic cancer [39] .…”

Section: Discussionmentioning

confidence: 99%

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

Ganepola

Rutledge

Suman

et al. 2014

WJGO

110

View full text Add to dashboard Cite

dures and instrumentation of RT-qPCR at an independent venue with a new cohort of cancer patients (n = 11), healthy controls (n = 11), and a group of high risk controls (n = 11). Receiver operating characteristic curve analysis was performed to assess the diagnostic capability of the three-microRNA panel. RESULTS:In the initial high throughput screening, 1220 known human microRNAs were screened for differential expression in pancreatic cancer patients versus controls. A subset of 42 microRNAs was then generated based on this data analysis and current published literature. Eight microRNAs were selected from the list of 42 targets for confirmation study, and three-microRNAs, miR-642b, miR-885-5p, and miR-22, were confirmed to show consistent expression between microarray and RT-qPCR. These three microRNAs were then validated and evaluated as a diagnostic panel with a new cohort of patients and controls and found to yield high sensitivity (91%) and specificity (91%) with an area under the curve of 0.97 (P < 0.001). Compared to the CA19-9 marker at 73%, the three-microRNA panel has higher sensitivity although CA19-9 has higher specificity of 100%. CONCLUSION:The identified panel of three microRNA biomarkers can potentially be used as a diagnostic tool for early stage pancreatic cancer. METHODS:Blood-based circulating microRNAs were profiled by high throughput screening using microarray analysis, comparing differential expression between early stage pancreatic cancer patients (n = 8) and healthy controls (n = 11). A panel of candidate microRNAs was generated based on the microarray signature profiling, including unsupervised clustering and statistical analysis of differential expression levels, and findings from the published literature. The selected candidate microRNAs were then confirmed using TaqMan real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) to further narrow down to a three-microRNA diagnostic panel. The three-microRNA diagnostic panel was validated with independent experimental proce- ORIGINAL ARTICLE 22January 15, 2014|Volume 6|Issue 1|

show abstract

Section: Discussionmentioning

confidence: 99%

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

Ganepola

Rutledge

Suman

et al. 2014

WJGO

110

View full text Add to dashboard Cite

show abstract

“…27 Importantly, pancreatitis has been shown to affect PDAC prognosis. 28 The Nrdc gene may provide another connection between pancreatitis and PDAC development. The deletion of Nrdc resulted in spontaneous chronic pancreatitis concomitant with acinar-to-ductal conversion and pancreatic deletion of Nrdc dramatically accelerated KRAS-driven PDAC development in mice.…”

Section: Recent Insights Into the Mechanisms Of Smoking-induced Carcinogenesis By The Other Risk Factorsmentioning

confidence: 99%

The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis

et al. 2020

View full text Add to dashboard Cite

Despite extensive research in the pathogenesis, early detection, and therapeutic approaches of pancreatic ductal adenocarcinoma (PDAC), it remains a devastating and incurable disease. As the global incidence and prevalence of PDAC continue to rise, there is a pressing need to place strong emphasis on its prevention. Although it is widely recognized that cigarette smoking, a potentially modifiable risk factor, has been linked to PDAC development, its contribution to prognosis is still uncertain. Moreover, the mechanistic pathways of PDAC progression secondary to smoking are various and lack a summative narration. Herein, we update and summarize the direct and indirect roles cigarette smoking plays on PDAC development, review literature to conclude the impact cigarette smoking has on prognosis, and postulate a comprehensive mechanism for cigarette smoking-induced PDAC.

show abstract

“…Idiopathic pancreatitis can be an initial presentation of pancreatic adenocarcinoma (14,15). Tumor-related pancreatitis can occur by ductal obstruction due to PDA, which may result in pseudocyst formation.…”

Section: Pdas With Attached Pseudocystsmentioning

confidence: 99%

Pancreas ductal adenocarcinoma with cystic features on cross-sectional imaging: radiologic-pathologic correlation

Youn

Rha

Jung

et al. 2018

Diagn Interv Radiol

View full text Add to dashboard Cite

Tu1511 Pancreatitis Prior to Pancreatic Cancer: Clinical Features and Influence on Outcome

Cited by 11 publications

References 0 publications

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis

Pancreas ductal adenocarcinoma with cystic features on cross-sectional imaging: radiologic-pathologic correlation

Contact Info

Product

Resources

About